Genentech suffers loss in Esbriet patent dispute with Sandoz, Teva and more – FiercePharma

24th March 2022

Genentech suffers loss in Esbriet patent dispute with Sandoz, Teva and more FiercePharma

OPUS IP on X (formerly Twitter)…

Twitter feed is not available at the moment.

RECENT PATENT NEWS…

Firm Advises PepStar Therapeutics on Patent Matters Related to Acquisition of Inflammation Drug Program by Gilead Sciences - Wilson Sonsini
Asked & Answered with Baker Botts IP Litigator Doug Kubehl: Erasing a $847M Verdict and 30 Years in Dallas - The Texas Lawbook
Stellantis Patents A Secret Head-Up Display You'll Only Be Able To Access By Speeding - CarBuzz
AbbVie’s Dividend Survived Humira’s Patent Cliff. Will Merck and Amgen’s? - 24/7 Wall St.

UK BUSINESS NEWS…

White House lifts tariffs on some Canadian goods as midterm elections loom
The little-known investment Martin Lewis wants you to understand...
Civil servant who juggled five jobs says he was 'surprised' to be charged with fraud
What is PHP and why did it spark a global cyber-security scramble?

Designed by Industrial Action

Copyright © 2026 OPUS IP Limited. All Rights Reserved

OPUS IP Limited: COMPANY & OTHER LEGAL INFORMATION